450 related articles for article (PubMed ID: 31658974)
21. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.
Romero-Gomez M; Kachru N; Zamorano MA; Darba J; Shreay S
Medicine (Baltimore); 2020 Dec; 99(50):e23506. PubMed ID: 33327291
[TBL] [Abstract][Full Text] [Related]
22. Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
Terai S; Buchanan-Hughes A; Ng A; Lee IH; Hasegawa K
J Gastroenterol; 2021 Mar; 56(3):274-284. PubMed ID: 33496858
[TBL] [Abstract][Full Text] [Related]
23. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.
En Li Cho E; Ang CZ; Quek J; Fu CE; Lim LKE; Heng ZEQ; Tan DJH; Lim WH; Yong JN; Zeng R; Chee D; Nah B; Lesmana CRA; Bwa AH; Win KM; Faulkner C; Aboona MB; Lim MC; Syn N; Kulkarni AV; Suzuki H; Takahashi H; Tamaki N; Wijarnpreecha K; Huang DQ; Muthiah M; Ng CH; Loomba R
Gut; 2023 Nov; 72(11):2138-2148. PubMed ID: 37491159
[TBL] [Abstract][Full Text] [Related]
24. Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies.
Golabi P; Owrangi S; Younossi ZM
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1():S1-S9. PubMed ID: 38813821
[TBL] [Abstract][Full Text] [Related]
25. Nonalcoholic fatty liver disease burden - Switzerland 2018-2030.
Goossens N; Bellentani S; Cerny A; Dufour JF; Jornayvaz FR; Mertens J; Moriggia A; Muellhaupt B; Negro F; Razavi H; Semela D; Estes C
Swiss Med Wkly; 2019 Dec; 149():w20152. PubMed ID: 31846507
[TBL] [Abstract][Full Text] [Related]
26. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship.
Muzica CM; Sfarti C; Trifan A; Zenovia S; Cuciureanu T; Nastasa R; Huiban L; Cojocariu C; Singeap AM; Girleanu I; Chiriac S; Stanciu C
Can J Gastroenterol Hepatol; 2020; 2020():6638306. PubMed ID: 33425804
[TBL] [Abstract][Full Text] [Related]
27. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
28. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Younossi Z; Tacke F; Arrese M; Chander Sharma B; Mostafa I; Bugianesi E; Wai-Sun Wong V; Yilmaz Y; George J; Fan J; Vos MB
Hepatology; 2019 Jun; 69(6):2672-2682. PubMed ID: 30179269
[TBL] [Abstract][Full Text] [Related]
29. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
[TBL] [Abstract][Full Text] [Related]
30. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis.
Noureddin M; Jones C; Alkhouri N; Gomez EV; Dieterich DT; Rinella ME;
Gastroenterology; 2020 Nov; 159(5):1985-1987.e4. PubMed ID: 32763241
[No Abstract] [Full Text] [Related]
31. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action.
Bril F; Cusi K
Diabetes Care; 2017 Mar; 40(3):419-430. PubMed ID: 28223446
[TBL] [Abstract][Full Text] [Related]
32. The incremental cost of non-alcoholic steatohepatitis and type 2 diabetes in the United States using real-world data.
Fishman J; Tapper EB; Dodge S; Miller K; Lewandowski D; Bogdanov A; Bonafede M
Curr Med Res Opin; 2023 Nov; 39(11):1425-1429. PubMed ID: 37740457
[TBL] [Abstract][Full Text] [Related]
33. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients.
C Gordon S; Fraysse J; Li S; Ozbay AB; Wong RJ
Am J Gastroenterol; 2020 Apr; 115(4):562-574. PubMed ID: 31833859
[TBL] [Abstract][Full Text] [Related]
34. Non-alcoholic fatty liver disease: A growing public health problem in Turkey.
Kaya E; Yılmaz Y
Turk J Gastroenterol; 2019 Oct; 30(10):865-871. PubMed ID: 31258135
[TBL] [Abstract][Full Text] [Related]
35. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
36. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
Oda K; Uto H; Mawatari S; Ido A
Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
[TBL] [Abstract][Full Text] [Related]
37. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
[TBL] [Abstract][Full Text] [Related]
38. Complications, morbidity and mortality of nonalcoholic fatty liver disease.
Mantovani A; Scorletti E; Mosca A; Alisi A; Byrne CD; Targher G
Metabolism; 2020 Oct; 111S():154170. PubMed ID: 32006558
[TBL] [Abstract][Full Text] [Related]
39. Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives.
Torre E; Di Matteo S; Bruno GM; Martinotti C; Valentino MC; Testino G; Rebora A; Bottaro LC; Colombo GL
Clinicoecon Outcomes Res; 2022; 14():607-618. PubMed ID: 36127889
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
